Atezolizumab Market Poised for Growth Supported by Rising Adoption in Various Cancer Types

 


Atezolizumab belongs to a class of drugs known as immune checkpoint inhibitor that works by blocking the interaction between PD-L1 protein and PD-1 and B7.1 proteins. This interaction normally helps tumors from being detected by the immune system. By blocking this interaction, atezolizumab helps the immune system identify and attack cancer cells. It is primarily used for the treatment of various cancers such as lung cancer, renal cell carcinoma, bladder cancer, Hodgkin’s lymphoma, head and neck squamous cell carcinoma. Atezolizumab is administered through intravenous injection and is well tolerated with mild side effects. The rising prevalence of cancer and increasing adoption of targeted therapies have fueled the consumption of atezolizumab.

The global atezolizumab market is estimated to be valued at US$ 308 million in 2024 and is expected to exhibit a CAGR of 3.0% over the forecast period of 2023 to 2030.

Key Takeaways
Key players: Mycovia Pharmaceuticals, Inc., Scynexis, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc. are some of the prominent players in the atezolizumab market. These players are focusing on expanding their production capacities and geographical reach through strategic partnerships and collaboration to meet the growing demand for atezolizumab.

Key opportunities: The rising preference for targeted therapies over conventional chemotherapy provides significant opportunities for atezolizumab in the treatment of various types of cancers. In addition, the pipeline drugs in combination with atezolizumab aimed at enhancing its efficacy further open up new prospects. Multiple ongoing clinical trials are also expected to widen the approved indications of atezolizumab.

Global expansion: To tap the high market potential, key players are focusing on expanding their presence in emerging markets. In addition, favorable regulations and increasing healthcare spending in countries like China, India are reshaping the competitive dynamics. Partnerships with regional players help global leaders strengthen their distribution network and better serve domestic cancer patients.

Market Drivers
One of the key drivers for the atezolizumab market is the high incidence and prevalence of various cancer types globally. According to WHO, cancer burden has risen to 18.1 million new cases and 9.6 million deaths in 2018. This growing cancer patient pool creates significant demand for novel immuno-oncology drugs like atezolizumab.

Additionally, the drug offers substantive advantages over existing treatment options such as chemotherapy which fuels its adoption. It exhibits a favorable safety profile with mild and self-limiting side effects. Further, atezolizumab also shows durable responses and improved survival rates in multiple cancer types which encourages its usage in clinical practice.

Market Restraints
High treatment cost of biologic drugs including atezolizumab poses significant affordability challenges, restricting their widespread adoption especially in low-income regions. Manufacturing complexity and stringent regulatory requirements also add to the overall cost burden. Further, lack of awareness regarding novel therapies in developing nations also restraints market growth potential to some extent.


Segment Analysis
The Atezolizumab market is dominated by the lung cancer sub segment. Lung cancer is the leading cause of cancer deaths globally, accounting for around 1.8 million deaths annually. Atezolizumab was one of the first immune checkpoint inhibitors approved for treatment of advanced non-small cell lung cancer (NSCLC). It is used in first-line and subsequent therapy of NSCLC with positive PD-L1 expression as determined by an FDA-approved test.

The bladder cancer sub segment is also gaining traction in the Atezolizumab market. Atezolizumab is indicated for treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Bladder cancer accounts for around 550,000 new cases annually worldwide.

Global Analysis
Regionally, North America dominates the global Atezolizumab market and the trend is likely to continue during the forecast period. High rate of cancers such as lung cancer and urinary bladder cancer in the US and Canada drives the regional market. Availability of favourable reimbursements for immunotherapy drugs further aids the regional growth. Asia Pacific is projected to witness the fastest growth during 2023-2030. Rising healthcare expenditure, growing awareness about cancer immunotherapy, and increasing access to diagnosis and treatment are boosting the regional market. Also, the presence of large patient pool in countries such as China and India supports the regional market expansion.

Comments

Post a Comment

Popular posts from this blog

Neuroendocrine Cancer is the fastest growing segment fueling the growth of Pituitary Cancer Market

Image
The pituitary cancer market comprises of medical treatment options for patients diagnosed with pituitary cancer. Pituitary cancers are rare tumors that start in the pituitary gland which is a pea-sized gland located at the base of the brain.  The global Pituitary Cancer Market is estimated to be valued at US$ 380.7 Mn in 2023 and is expected to exhibit a CAGR of 9.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.    Market key trends: One of the key trends fueling the growth of the pituitary cancer market is rising preference of targeted drug therapy over conventional chemotherapy. Targeted drug therapies mainly include somatostatin analogs and dopamine agonists which directly act on cancer cells and have less side effects compared to chemotherapy. These targeted drugs are effective in controlling symptoms and slowing tumor growth in patients with hormone secreting pituitary adenomas and carcinomas. The targe...
Read more

Enhancing Patient Care and Comfort: The Evolution of Hospital Beds

Image
  Hospital beds play a crucial role in patient care, providing comfort, safety, and functionality for individuals requiring medical attention. Over the years, advancements in technology and design have revolutionized hospital beds, leading to improved patient outcomes and caregiver efficiency. From basic adjustable beds to sophisticated models equipped with cutting-edge features, the evolution of hospital beds has transformed the healthcare landscape. Evolution of Hospital Beds: Historically, hospital beds were simple in design, primarily consisting of a metal frame with adjustable height and manual controls. However, as medical practices advanced and patient needs became more complex, the demand for more versatile and ergonomic hospital beds grew. In recent decades, significant strides have been made in the development of hospital bed technology. Modern hospital beds are designed with a focus on patient comfort, safety, and mobility. Features such as electronic controls, motorize...
Read more

Dry Eye Disease Market is Estimated to Witness High Growth Owing to Rising Awareness About Disease Management

Image
  Dry eye disease, also known as keratoconjunctivitis sicca, is a multifactorial disease of the ocular surface characterized by lack of sufficient moisture and tear film instability. Common symptoms of dry eye include stingy or burning sensation in eyes and blurred vision.   Market Dynamics : The Dry Eye Disease Market is witnessing high growth owing to rising awareness about disease management and increasing number of people experiencing symptoms of dry eyes. According to the report, increasing usage of electronic devices and prolonged screen time is a major driver fueling the demand for dry eye treatments. Additionally, growing geriatric population worldwide who are more prone to dry eyes is also contributing to the market growth. Availability of various treatment options along with new product launches is further expected to boost the market during forecast period.   Increasing Prevalence of Dry Eye Disease is Driving Market Growth   One of the major market drive...
Read more